ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 2386

Landscape of Immune Cells and Autoimmunity in Systemic Lupus Erythematosus Patients with Obesity
Abstract Number: 1222

Large Language Model-driven Sentiment Analysis for Facilitating Fibromyalgia Diagnosis
Abstract Number: 2181

Large Pediatric Cohort with ANCA-associated Vasculitis at a Single Institution: Patient Characteristics, Clinical Course, and Outcomes
Abstract Number: 0576

Less Than 15% Unfavourable Pregnancy Outcomes in Patients with Recent-onset Axial Spondyloarthritis: The Analysis of the 10 Years DESIR Cohort Follow-up
Abstract Number: 1815

Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel
Abstract Number: L15

LEVI-04, a Novel neurotrophin-3 Inhibitor, Substantially Improves Pain and Function Without Deleterious Effects on Joint Structure in People with Knee Osteoarthritis: A Randomized Controlled Phase II Trial
Abstract Number: 0983

Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey
Abstract Number: 0971

Ligand-Receptor Analysis Reveals Myeloid-Mediated Pro-Inflammatory Responses and Loss of Mesenchymal Signaling Driven by TNFR1 in Experimental Pulmonary Hypertension
Abstract Number: 0166

Limitations in Activities of Daily Living Among Individuals with SLE
Abstract Number: 0709

Linear Combination of Principal Components Achieves Top Performance in Identifying Rheumatologist-Diagnosed Systemic Sclerosis from Electronic Health Records
Abstract Number: 1271

Linkage of the Childhood Arthritis and Rheumatology Research Alliance Registry with the Pediatric Health Information System: Creation of a Comprehensive Childhood-Onset Lupus Dataset
Abstract Number: 1787

Linking Transcriptomic Profiles of Kidney and Blood Samples Provides Insight into Identification of Lupus Nephritis
Abstract Number: 2546

Lipocalin-2 Drives Neuropsychiatric and Cutaneous SLE Through Regulation of Immune Cell Recruitment in Target Organs
Abstract Number: 0292

Liver Disease Complicating Familial Mediterranean Fever: A Study on 57 Patients from the French Adult JIR Cohort
Abstract Number: PP02

Living Well with a Rare Rheumatic Disease – Becoming a “Precision” Patient on the Horizon of Precision Medicine
Abstract Number: PP11

Living Well with Chronic Illness: Decades with MCTD
Abstract Number: 1240

Living with Antiphospholipid Antibodies: A Photovoice Exploration
Abstract Number: 1312

Long Term Proficiency and Clinical Outcomes of a Novel Fellow’s Injection Clinic
Abstract Number: 1345

Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study
Abstract Number: 1120

Long-Term Echocardiographic Findings in Idiopathic Recurrent Pericarditis Patients Treated with Anakinra
Abstract Number: 0788

Long-term Effectiveness of a Lifestyle Intervention for Osteoarthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial
Abstract Number: 0530

Long-term Effectiveness of a Lifestyle Intervention for Rheumatoid Arthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial
Abstract Number: 2252

Long-term Efficacy of Filgotinib Monotherapy and Combination Therapy: Interim Results from a Post Hoc Analysis of the FINCH 4 Study
Abstract Number: 1104

Long-term Follow-up of Patients with Positive Cryofibrinogen Test During the COVID-19 Era
Abstract Number: 1246

Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies
Abstract Number: 0458

Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Abstract Number: 2501

Long-term Remission off Therapy (LTROT) Is Possible in Non-infectious Aortitis with DMARDs with Low Risk of Secondary Adrenal Insufficiency
Abstract Number: 2482

Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies
Abstract Number: 1094

Longitudinal Analysis of Serum Urate in Prediabetic Phase
Abstract Number: 0238

Longitudinal Assessment of CD8+ T Cell Responses to SARS-CoV-2 Pre- and Post-breakthrough Infection and Its Association with COVID-19 Severity in Immunosuppressed Individuals
Abstract Number: 2357

Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studies
Abstract Number: 2490

Longitudinal Kidney Function Trajectories in Patients Enrolled in the Plasma Exchange and Glucocorticoids in ANCA-Associated Vasculitis Trial
Abstract Number: 0270

Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease
Abstract Number: 1227

Longitudinal Patterns of Fibromyalgia Phenotypes in Patients with Systemic Lupus Erythematosus
Abstract Number: 1656

Loss of Nr4a1 Expression Protects Cartilage During Post-traumatic Osteoarthritis
Abstract Number: 2184

Loss to Follow up After Transfer from Pediatric to Adult Care in Patients with JIA or jSLE
Abstract Number: 1396

Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis
Abstract Number: 1607

Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Abstract Number: 2351

Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Abstract Number: 0565

Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study
Abstract Number: 2270

Low Yield of Routine Serological Screening for Hepatitis B in Patients with Rheumatoid Arthritis Starting Rituximab Therapy in a Non-Endemic Country
Abstract Number: 0467

Lung Involvement in Early Rheumatoid Arthritis, Analysis of ERA UCLouvain Brussels FINDRA Cohort
Abstract Number: 0853

Lung Ultrasound in Rheumatoid Arthritis and Systemic Sclerosis: Accuracy of B-line and Pleural Assessment
Abstract Number: 0630

Lupus Lymphocyte Activation Score of Pathologic T and B Cell Phenotypes Increased in Patients at Risk of Systemic Lupus Erythematosus
Abstract Number: 0656

Lupus Myocarditis: Clinical Characteristics, Cardiac Magnetic Resonance Imaging Findings and Outcomes
Abstract Number: 1511

Lupus Nephritis and Response to Treatment in Latin America
Abstract Number: 1489

Lupus Nephritis Clinical and Serological Responses at 12 Months: Implications for Repeat Biopsy, Intensified Immunosuppression or Additional Anti-proteinuric Therapy
Abstract Number: 2591

Lupus-Related Reproductive Health Experiences and Needs of Women of Childbearing Age: A Qualitative Study

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].